An affiliate marketer of Tokyo-based Astellas Pharma Inc.

‘We anticipate continuing our successful and solid collaboration with Seattle Genetics.’.. Agensys, Seattle Genetics to co-develop second antibody-drug conjugate for multiple sound tumors Seattle Genetics, Inc. and Agensys, Inc., an affiliate marketer of Tokyo-based Astellas Pharma Inc. , today announced that Seattle Genetics has exercised an option to co-develop a second antibody-drug conjugate under the businesses’ existing ADC collaboration agreement. The ADC, known as ASG-22ME , targets the Nectin-4 antigen, which is normally expressed on multiple solid tumors. During the first quarter of 2011, Agensys submitted an investigational new drug software to the U.S.Taveira-DaSilva, M.D., Ph.D., Hye-Seung Lee, Ph.D., Jeffrey P. Krischer, Ph.D., and Bruce C. Trapnell, M.D. For the National Institutes of Health Rare Lung Diseases Consortium and the MILES Trial Group: Efficacy and Security of Sirolimus in Lymphangioleiomyomatosis.. 2011 National Report Card on Lung Tumor notes significant change in grade for early detection Today Yearly Assessment Notes Significant Switch in Grade for Early Detection and Progress in Federal Response, Lung Cancer Alliance , the leading national support and advocacy voice for all those at risk for or living with lung cancer, issued its annual 2011 National Report Card on Lung Cancer, an overall assessment of the country’s response to the continuing high mortality of lung cancer, the leading reason behind cancer death.